Tags

Type your tag names separated by a space and hit enter

Component-resolved diagnosis of kiwifruit allergy with purified natural and recombinant kiwifruit allergens.
J Allergy Clin Immunol 2010; 125(3):687-94, 694.e1JA

Abstract

BACKGROUND

Kiwifruit is one of the most common causes of food allergic reactions. Component-resolved diagnostics may enable significantly improved detection of sensitization to kiwifruit.

OBJECTIVE

To evaluate the use of individual allergens for component-resolved in vitro diagnosis of kiwifruit allergy.

METHODS

Thirty patients with a positive double-blind placebo-controlled food challenge to kiwifruit, 10 atopic subjects with negative open provocation to kiwifruit, and 5 nonatopic subjects were enrolled in the study. Specific IgE to 7 individual allergens (nAct d 1-5 and rAct d 8-9) and allergen extracts was measured by ImmunoCAP.

RESULTS

The diagnostic sensitivities of the commercial extract and of the sum of single allergens were 17% and 77%, respectively, whereas diagnostic specificities were 100% and 30%. A combination of the kiwi allergens Act d 1, Act d 2, Act d 4, and Act d 5 gave a diagnostic sensitivity of 40%, whereas diagnostic specificity remained high (90%). Exclusion of the Bet v 1 homolog recombinant (r) Act d 8 and profilin rAct d 9 from this allergen panel reduced sensitivity to 50% but increased specificity to 40%. Kiwifruit-monosensitized patients reacted more frequently (P < .001) with Act d 1 than polysensitized patients, whereas the latter group reacted more frequently with rAct d 8 (P = .004).

CONCLUSION

Use of single kiwifruit allergen ImmunoCAP increases the quantitative test performance and diagnostic sensitivity compared with the commercial extract. Bet v 1 homolog and profilin are important allergens in pollen-related kiwifruit allergy, whereas actinidin is important in monoallergy to kiwifruit, in which symptoms are often more severe.

Authors+Show Affiliations

Department of Pathophysiology, Medical University of Vienna, Vienna, Austria.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20061012

Citation

Bublin, Merima, et al. "Component-resolved Diagnosis of Kiwifruit Allergy With Purified Natural and Recombinant Kiwifruit Allergens." The Journal of Allergy and Clinical Immunology, vol. 125, no. 3, 2010, pp. 687-94, 694.e1.
Bublin M, Pfister M, Radauer C, et al. Component-resolved diagnosis of kiwifruit allergy with purified natural and recombinant kiwifruit allergens. J Allergy Clin Immunol. 2010;125(3):687-94, 694.e1.
Bublin, M., Pfister, M., Radauer, C., Oberhuber, C., Bulley, S., Dewitt, A. M., ... Ballmer-Weber, B. K. (2010). Component-resolved diagnosis of kiwifruit allergy with purified natural and recombinant kiwifruit allergens. The Journal of Allergy and Clinical Immunology, 125(3), pp. 687-94, 694.e1. doi:10.1016/j.jaci.2009.10.017.
Bublin M, et al. Component-resolved Diagnosis of Kiwifruit Allergy With Purified Natural and Recombinant Kiwifruit Allergens. J Allergy Clin Immunol. 2010;125(3):687-94, 694.e1. PubMed PMID: 20061012.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Component-resolved diagnosis of kiwifruit allergy with purified natural and recombinant kiwifruit allergens. AU - Bublin,Merima, AU - Pfister,Marina, AU - Radauer,Christian, AU - Oberhuber,Christina, AU - Bulley,Sean, AU - Dewitt,Asa Marknell, AU - Lidholm,Jonas, AU - Reese,Gerald, AU - Vieths,Stefan, AU - Breiteneder,Heimo, AU - Hoffmann-Sommergruber,Karin, AU - Ballmer-Weber,Barbara K, Y1 - 2010/01/12/ PY - 2009/05/12/received PY - 2009/10/14/revised PY - 2009/10/15/accepted PY - 2010/1/12/entrez PY - 2010/1/12/pubmed PY - 2010/4/8/medline SP - 687-94, 694.e1 JF - The Journal of allergy and clinical immunology JO - J. Allergy Clin. Immunol. VL - 125 IS - 3 N2 - BACKGROUND: Kiwifruit is one of the most common causes of food allergic reactions. Component-resolved diagnostics may enable significantly improved detection of sensitization to kiwifruit. OBJECTIVE: To evaluate the use of individual allergens for component-resolved in vitro diagnosis of kiwifruit allergy. METHODS: Thirty patients with a positive double-blind placebo-controlled food challenge to kiwifruit, 10 atopic subjects with negative open provocation to kiwifruit, and 5 nonatopic subjects were enrolled in the study. Specific IgE to 7 individual allergens (nAct d 1-5 and rAct d 8-9) and allergen extracts was measured by ImmunoCAP. RESULTS: The diagnostic sensitivities of the commercial extract and of the sum of single allergens were 17% and 77%, respectively, whereas diagnostic specificities were 100% and 30%. A combination of the kiwi allergens Act d 1, Act d 2, Act d 4, and Act d 5 gave a diagnostic sensitivity of 40%, whereas diagnostic specificity remained high (90%). Exclusion of the Bet v 1 homolog recombinant (r) Act d 8 and profilin rAct d 9 from this allergen panel reduced sensitivity to 50% but increased specificity to 40%. Kiwifruit-monosensitized patients reacted more frequently (P < .001) with Act d 1 than polysensitized patients, whereas the latter group reacted more frequently with rAct d 8 (P = .004). CONCLUSION: Use of single kiwifruit allergen ImmunoCAP increases the quantitative test performance and diagnostic sensitivity compared with the commercial extract. Bet v 1 homolog and profilin are important allergens in pollen-related kiwifruit allergy, whereas actinidin is important in monoallergy to kiwifruit, in which symptoms are often more severe. SN - 1097-6825 UR - https://www.unboundmedicine.com/medline/citation/20061012/Component_resolved_diagnosis_of_kiwifruit_allergy_with_purified_natural_and_recombinant_kiwifruit_allergens_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0091-6749(09)01544-9 DB - PRIME DP - Unbound Medicine ER -